Valuation: Allied Corp.

Market Cap 1.3M 1.16M 1.09M 987K 1.86M 126M 1.87M 13.06M 5.1M 64.14M 4.89M 4.79M 206M P/E 2023
-2.13x
P/E 2024 -2.52x
Enterprise Value 7.55M 6.75M 6.29M 5.72M 10.77M 730M 10.85M 75.64M 29.55M 371M 28.35M 27.74M 1.19B EV / Sales 2023
394,366,816x
EV / Sales 2024 171,944,593x
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0.01
1 year 0
Extreme 1.0E-6
0.01
3 years 0
Extreme 1.0E-6
0.25
5 years 0
Extreme 1.0E-6
2.15
10 years 0
Extreme 1.0E-6
4.5
Manager TitleAgeSince
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer 71 -
Corporate Officer/Principal - 2020-05-01
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - 2020-05-01
Director/Board Member - 2024-10-20
Date Insider Type Main position Quantity % Market Cap. Importance
4/25/23 Buy

Director

80,000 0.0824%
9/22/20 Buy

Chief Executive Officer

10,000 0.0118%
9/22/20 Other

Chief Executive Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 117
-3.26%+1.19%+37.58%+103.49% 1,060B
-1.73%-0.99%+35.02%+61.54% 623B
-0.85%+3.99%+16.90%+81.28% 480B
-1.66%-1.72%+63.59%+35.25% 352B
-1.33%+2.12%+22.35%+42.08% 345B
-1.72%+0.41%+11.31%+34.51% 274B
-1.81%-2.04%-5.87%+10.81% 249B
-2.17%+0.21%+38.52%+50.29% 223B
-0.77%-0.26%+24.41%+96.00% 182B
Average -1.51%-0.44%+27.09%+57.25% 378.8B
Weighted average by Cap. -1.94%+0.04%+30.23%+67.26%

Financials

2023 2024
Net sales 0.07 0.06 0.06 0.05 0.1 6.97 0.1 0.72 0.28 3.55 0.27 0.26 11.4 0.1 0.09 0.08 0.07 0.14 9.3 0.14 0.96 0.38 4.73 0.36 0.35 15.21
Net income -10.68M -9.54M -8.9M -8.08M -15.22M -1.03B -15.34M -107M -41.78M -525M -40.08M -39.21M -1.69B -3.98M -3.55M -3.31M -3.01M -5.67M -385M -5.71M -39.83M -15.56M -196M -14.93M -14.6M -629M
Net Debt 5.65M 5.05M 4.71M 4.28M 8.06M 547M 8.12M 56.62M 22.12M 278M 21.22M 20.76M 894M 6.25M 5.58M 5.21M 4.73M 8.91M 604M 8.98M 62.58M 24.45M 307M 23.45M 22.95M 988M
Projected Income Statement - Annual - Allied Corp.
Logo Allied Corp.
Allied Corp. is an international medical cannabis production company. The Company is engaged in researching, creating, and producing targeted cannabinoid health solutions. It focuses on the development of Colombian produced medicinal cannabis for patients with conditions potentially suitable for treatment. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinson’s disease, Tourette’s syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI). Its core hemp-derived cannabidiol (CBD) brands are Tactical Relief Brand, Equilibrium Bio and MaXXa. The Tactical Relief brand's flagship product is a hemp-derived CBD tincture for sale in the United States. The Equilibrium Bio brand is primarily focused on hydration and recovery areas. The MaXXa brand develops natural CBD-infused cosmetics and beauty products.
Employees
-
  1. Stock Market
  2. Stocks
  3. ALID Stock